X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5887) 5887
Publication (638) 638
Newsletter (450) 450
Book Review (111) 111
Book Chapter (18) 18
Dissertation (16) 16
Newspaper Article (14) 14
Conference Proceeding (13) 13
Book / eBook (9) 9
Magazine Article (7) 7
Trade Publication Article (2) 2
Data Set (1) 1
Paper (1) 1
Streaming Video (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4969) 4969
index medicus (3220) 3220
pharmacology & pharmacy (2689) 2689
cytochrome p-450 (2563) 2563
male (2411) 2411
female (2255) 2255
genotype (2089) 2089
cytochrome p-450 cyp2c19 (1634) 1634
adult (1582) 1582
middle aged (1567) 1567
aryl hydrocarbon hydroxylases - genetics (1519) 1519
pharmacogenetics (1493) 1493
metabolism (1378) 1378
pharmacokinetics (1244) 1244
genetic aspects (1222) 1222
cytochrome p-450 enzyme system - genetics (1188) 1188
polymorphism, genetic (1173) 1173
cytochrome p-450 enzyme system - metabolism (1123) 1123
aged (1053) 1053
research (995) 995
cyp2c19 (933) 933
cytochrome p450 (854) 854
physiological aspects (846) 846
polymorphism (836) 836
genetic polymorphisms (794) 794
drug interactions (784) 784
enzymes (747) 747
analysis (736) 736
phenotype (711) 711
alleles (704) 704
cytochrome p-450 cyp2d6 - genetics (701) 701
mixed function oxygenases - genetics (685) 685
ticlopidine - analogs & derivatives (671) 671
cytochrome p-450 cyp2c19 - genetics (659) 659
animals (640) 640
clopidogrel (636) 636
aryl hydrocarbon hydroxylases - metabolism (584) 584
metabolites (525) 525
pharmacology (522) 522
cyp2d6 (504) 504
cytochrome p-450 cyp2c9 (500) 500
young adult (500) 500
in-vitro (492) 492
treatment outcome (483) 483
pharmacology/toxicology (481) 481
polymorphism, single nucleotide (480) 480
toxicology (468) 468
polymorphisms (456) 456
drug metabolism (446) 446
care and treatment (445) 445
cytochrome (436) 436
gene frequency (433) 433
omeprazole (431) 431
adolescent (409) 409
drugs (408) 408
human liver-microsomes (407) 407
drug therapy (401) 401
health aspects (400) 400
aryl hydrocarbon hydroxylases (385) 385
platelet aggregation inhibitors - therapeutic use (384) 384
cyp2c9 (381) 381
hydroxylation (379) 379
dose-response relationship, drug (370) 370
mixed function oxygenases - metabolism (369) 369
risk factors (369) 369
proton pump inhibitors (362) 362
ticlopidine - therapeutic use (362) 362
cytochrome p-450 cyp2d6 - metabolism (355) 355
genes (344) 344
biomedicine (330) 330
biochemistry & molecular biology (327) 327
medicine & public health (324) 324
population (323) 323
genetic research (322) 322
cancer (319) 319
aged, 80 and over (318) 318
genetics & heredity (318) 318
association (313) 313
area under curve (311) 311
warfarin (303) 303
liver (300) 300
pharmacogenomics (296) 296
percutaneous coronary intervention (295) 295
therapy (293) 293
asian continental ancestry group - genetics (292) 292
internal medicine (292) 292
biotransformation (291) 291
genotype & phenotype (290) 290
cytochrome p-450 cyp3a - genetics (287) 287
identification (285) 285
inhibition (280) 280
dosage and administration (277) 277
genetic-polymorphism (276) 276
expression (275) 275
polymorphism, genetic - genetics (275) 275
article (274) 274
polymerase chain reaction (272) 272
microsomes, liver - enzymology (271) 271
genetics (264) 264
medicine (264) 264
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6274) 6274
Japanese (138) 138
Chinese (33) 33
Russian (26) 26
German (19) 19
Spanish (13) 13
French (9) 9
Polish (6) 6
Norwegian (5) 5
Danish (3) 3
Korean (3) 3
Czech (1) 1
Hebrew (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2013, Volume 61, Issue 8, pp. 872 - 879
Objectives This study sought to determine whether known genetic, drug, dietary, compliance, and lifestyle factors affecting clopidogrel absorption and... 
Cardiovascular | Internal Medicine | pharmacokinetics | risk factors | receptors | drugs | platelets | CARDIAC & CARDIOVASCULAR SYSTEMS | EFFICACY | GENOTYPE | REACTIVITY | TRIAL | CIGARETTE-SMOKING | PARAOXONASE-1 | RESISTANCE | PRASUGREL | ABSORPTION | ASSOCIATION | Area Under Curve | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Aryl Hydrocarbon Hydroxylases - genetics | Male | Drug Monitoring - methods | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - blood | Ticlopidine - administration & dosage | Adult | Female | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Ticlopidine - pharmacokinetics | Drug Therapy, Combination | Platelet Aggregation - genetics | Cardiovascular Diseases - etiology | 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacokinetics | Platelet Function Tests - methods | Aryldialkylphosphatase - genetics | Ticlopidine - analogs & derivatives | Polymorphism, Genetic | Cross-Over Studies | Smoking - metabolism | Confounding Factors (Epidemiology) | Proton Pump Inhibitors - pharmacokinetics | Blood Coagulation - drug effects | ATP-Binding Cassette, Sub-Family B, Member 1 - genetics | Cytochrome P-450 CYP2C19 | ATP Binding Cassette Transporter, Sub-Family B | Cardiovascular Diseases - psychology | Patient Compliance | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Phosphates | Drugs | Prescribing | Medical colleges | Continuing medical education | Metabolites | Vasodilators | Cytochrome P-450 | Physiological aspects | Proton pump inhibitors | Genetic aspects | Patient compliance | Research institutes | Studies | Cytochrome | Body mass index | Nutrition research | Genotype & phenotype | Demographics | Drug therapy | Acute coronary syndromes | Drug dosages
Journal Article
PLoS ONE, ISSN 1932-6203, 01/2017, Volume 12, Issue 1, p. e0169214
Mesial temporal lobe epilepsy is the most common form of adult epilepsy in surgical series. Currently, the only characteristic used to predict poor response to... 
METAANALYSIS | RISK PREDICTION | HIPPOCAMPAL SCLEROSIS | MULTIDISCIPLINARY SCIENCES | RESISTANCE | POLYMORPHISM | ANTIEPILEPTIC DRUGS | BLOOD-BRAIN-BARRIER | EXPRESSION | Cytochrome P-450 CYP1A1 - genetics | Cytochrome P-450 CYP1B1 - genetics | Cytochrome P-450 CYP2D6 - genetics | Humans | Anticonvulsants - therapeutic use | Cytochrome P-450 CYP2C19 - genetics | Epilepsy, Temporal Lobe - drug therapy | Genotype | Cytochrome P-450 CYP2E1 - genetics | Hippocampus - pathology | Cytochrome P-450 CYP2C9 - genetics | Hippocampus - metabolism | Algorithms | Cytochrome P-450 CYP3A - genetics | Cytochrome P-450 CYP1A2 - genetics | Epilepsy, Temporal Lobe - genetics | Polymorphism, Single Nucleotide - genetics | Multidrug Resistance-Associated Proteins - genetics | ATP Binding Cassette Transporter, Sub-Family B - genetics | Drugs | Evaluation | Drug abuse | Control | Care and treatment | Laws, regulations and rules | Reports | Health aspects | Therapy | Neurosciences | Nuclear magnetic resonance--NMR | Laboratories | Epilepsy | Genes | Genomics | Medical services | Systematic review | Single-nucleotide polymorphism | Antiepileptic agents | Sclerosis | Proteins | Prediction models | Surgery | Drug metabolism | Population | Genetics | Mathematical models | CYP2D6 protein | Temporal lobe | Cytochrome P450 | Breast cancer | CYP1A2 protein | Metabolism | Gene expression | Patients | Model accuracy | Studies | Neurology | Transporter | Hippocampus | Nuclear magnetic resonance | NMR | Predictions
Journal Article
Journal of Pharmaceutical and Biomedical Analysis, ISSN 0731-7085, 09/2008, Volume 48, Issue 1, pp. 92 - 99
The current study focused on the development of an automated IC cocktail assay in a miniaturized 384 well assay format. This was developed in combination with... 
Human liver microsomes | Drug-drug interactions | High-performance liquid chromatography | Cytochrome P450 | human liver microsomes | PHRMA PERSPECTIVE | CHEMISTRY, ANALYTICAL | IN-VITRO COCKTAIL | VALIDATION | TANDEM MASS-SPECTROMETRY | PROBE-DOSING STRATEGY | drug-drug interactions | LIQUID-CHROMATOGRAPHY | ENZYMES | INHIBITION ASSESSMENT | high-performance liquid chromatography | PHARMACOLOGY & PHARMACY | GUARD CARTRIDGE EXTRACTION | Cytochrome P-450 CYP2C9 | Diclofenac - pharmacology | Humans | Microsomes, Liver - metabolism | Cytochrome P-450 Enzyme System - metabolism | Cytochrome P-450 CYP3A - analysis | Dextromethorphan - metabolism | Cytochrome P-450 CYP2D6 - analysis | Reference Standards | Tacrine - pharmacology | Drug Interactions | Time Factors | Sensitivity and Specificity | Inhibitory Concentration 50 | Biological Assay | Oxidoreductases, N-Demethylating - metabolism | Tandem Mass Spectrometry - methods | Tacrine - metabolism | Aryl Hydrocarbon Hydroxylases - pharmacology | Cytochrome P-450 Enzyme System - analysis | Reproducibility of Results | Dextromethorphan - pharmacology | Microsomes, Liver - chemistry | Cytochrome P-450 CYP1A2 - metabolism | Aryl Hydrocarbon Hydroxylases - analysis | Aryl Hydrocarbon Hydroxylases - metabolism | Oxidoreductases, N-Demethylating - pharmacology | Substrate Specificity - drug effects | Cytochrome P-450 CYP2C19 | Cytochrome P-450 CYP3A - metabolism | Cytochrome P-450 CYP2D6 - metabolism | Cytochrome P-450 Enzyme System - genetics | Midazolam - metabolism | Kinetics | Miniaturization | Chromatography, Liquid - methods | Midazolam - pharmacology | Cytochrome P-450 CYP2B6 | Cytochrome P-450 CYP1A2 - analysis | Diclofenac - metabolism | Hydrogen-Ion Concentration | Index Medicus
Journal Article
Clinical Chemistry, ISSN 0009-9147, 10/2009, Volume 55, Issue 10, pp. 1770 - 1782
Journal Article
Pharmacogenetics and genomics, ISSN 1744-6872, 2008, Volume 18, Issue 6, pp. 515 - 523
PURPOSE: The anticancer agent, cyclophosphamide, is metabolized by cytochrome P450 (CYP), glutathione S-transferase (GST) and aldehyde dehydrogenase (ALDH)... 
4-hydroxycyclophosphamide | Population pharmacokinetics | Cyclophosphamide | Pharmacogenetics | SYSTEMIC-LUPUS-ERYTHEMATOSUS | GENETIC POLYMORPHISMS | FUNCTIONAL-CHARACTERIZATION | PULSE CYCLOPHOSPHAMIDE | TANDEM MASS-SPECTROMETRY | TRANSFERASE A1 PROMOTER | population pharmacokinetics | BREAST-CANCER | HIGH-DOSE CYCLOPHOSPHAMIDE | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | GENETICS & HEREDITY | cyclophosphamide | PHARMACOLOGY & PHARMACY | HUMAN LIVER | SIMULTANEOUS QUANTIFICATION | pharmacogenetics | Cytochrome P-450 CYP2C9 | Cyclophosphamide - analogs & derivatives | Oxidoreductases, N-Demethylating - genetics | Humans | Middle Aged | Aryl Hydrocarbon Hydroxylases - genetics | Male | DNA Primers - genetics | Neoplasms, Germ Cell and Embryonal - genetics | Breast Neoplasms - metabolism | Ovarian Neoplasms - genetics | Glutathione Transferase - genetics | Cytochrome P-450 CYP3A - genetics | Base Sequence | Adult | Female | Neoplasms, Germ Cell and Embryonal - drug therapy | Ovarian Neoplasms - metabolism | Ovarian Neoplasms - drug therapy | Glutathione S-Transferase pi - genetics | Aldehyde Dehydrogenase - genetics | Neoplasms, Germ Cell and Embryonal - metabolism | Breast Neoplasms - drug therapy | Polymorphism, Genetic | Breast Neoplasms - genetics | Cytochrome P-450 CYP2C19 | Adolescent | Cytochrome P-450 Enzyme System - genetics | Cyclophosphamide - pharmacokinetics | Cytochrome P-450 CYP2B6 | Cohort Studies | Index Medicus
Journal Article
Journal Article
Biomedical and Environmental Sciences, ISSN 0895-3988, 08/2018, Volume 31, Issue 8, pp. 586 - 595
Journal Article